

GENFIT AND SERVIER EXTEND THEIR STRATEGIC RESEARCH ALLIANCE THROUGH 2010

Lille (France), Cambridge (Massachusetts, USA), January 8, 2009 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of research and development of drugs, focusing on early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announced the extension of its drug discovery alliance until December 2010 with SERVIER, the first independent French pharmaceutical group.

Initiated in 2004 and set to end in December 2008, the alliance with SERVIER relies primarily on two research programs as part of compound series SERX1 and is dedicated to the treatment of insulin resistance and type 2 diabetes. In these programs, researches focused in partnership on the characterization of two entirely innovative targets, one of which being an orphan nuclear receptor.

To date, the two companies have successfully garnered multiple advances in the development of these targets. Major steps toward validation of these targets in the referenced therapeutic indication were recently achieved. Furthermore, the implementation of high-throughput screening strategies now allows the initiation of drug discovery program. Various milestones resulting from this collaboration are expected this year.

Jean-François Mouney, CEO of GENFIT, announced: “We are very pleased to improve and extend this partnership with SERVIER. Together, we are facing a scientific challenge aiming at discovering new therapeutic solutions to treat multiple risk factors associated with diabetes and obesity. We are convinced that, in the long run, this collaboration will generate a significant value both for the Company and our shareholders”.

Bernard Marchand, Head of Research at SERVIER Laboratories, added: “The renewal of this partnership is very important to us because it embodies many years of joint efforts that enabled corroborating an innovative target in the treatment of metabolic diseases”.

About GENFIT:

A biopharmaceutical company, GENFIT studies the regulation and function of genes implicated in many of the most widespread diseases. GENFIT’s scientists identify new therapeutic targets and develop drug candidates designed specifically for such targets. GENFIT’s programs, conducted in partnership with pharmaceutical companies which include SANOFI-AVENTIS, SOLVAY GROUP, PIERRE FABRE, MERCK AG and SERVIER, treat the most prevalent metabolic diseases. GENFIT’s development of proprietary drugs focuses on early diagnosis, prevention and treatment of micro and macro-vascular diseases in pre-diabetes and diabetes. GENFIT is also committed in research programmes in specific neurodegenerative diseases. GENFIT possesses a rich and diversified pipeline of drug candidates at different stages of development – development carried out by GENFIT alone or in partnership. GENFIT’s lead proprietary compound, GFT505, is currently in Phase II and another compound in partnership with SANOFI-AVENTIS (AVE0897) is now completing Phase I. With facilities in Lille, France, and Cambridge, MA (USA), the company has over 130 employees on staff, including over 100 scientists. GENFIT is a public company listed on the Alternext by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney - Chairman of the Management Board
+ 33 (0)3 2016 4000

MILESTONES – Press Relations

Bruno Arabian
+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 - milestones@milestones-fr.com

Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in both French and English languages. In the event of any differences between the two texts, the French language version shall supersede.